Pfizer Acquires Metsera’s Obesity Assets Amid Mixed FY25 Financial Results

Pfizer’s fiscal year 2025 results show a mixed performance, prompting the company to focus on its research and development strategy for future growth. The pharmaceutical giant has recently acquired obesity-related assets from Metsera, signaling an effort to expand its portfolio in this area. Pfizer’s move comes as it seeks to address challenges and capitalize on opportunities in the healthcare market.

The FY25 financial report highlights uneven outcomes for Pfizer, with certain areas underperforming while others showed promise. In response, the company is shifting attention toward innovation and strategic acquisitions. The addition of Metsera’s obesity assets aligns with Pfizer’s broader goals of addressing global health concerns through targeted therapies. This acquisition is part of a larger initiative that includes exploring artificial intelligence applications in drug development and other advanced technologies aimed at improving patient outcomes.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 3, 2026

Author

GOAI